Adjunctive Hyperbaric Oxygen Therapy in Refractory Crohn's Disease: An Observational Study | Canada Hyperbarics Skip to main content
Study Gastroenterol Res Pract 2021

Adjunctive Hyperbaric Oxygen Therapy in Refractory Crohn's Disease: An Observational Study

Feitosa M, Parra R, Machado V, Vilar G, Aquino J, Rocha J, et al. — Gastroenterol Res Pract, 2021

Tier 2, Indexed

Automatically imported from PubMed based on relevance criteria.

Summary

What Researchers Did

This study investigated how effective hyperbaric oxygen therapy (HBOT) was for patients with Crohn's disease complications that had not responded to standard medical treatments.

What They Found

Out of 40 patients with refractory Crohn's disease complications, 32 patients (82.5%) achieved complete healing after receiving adjunctive HBOT. Patients with pyoderma gangrenosum showed the highest healing rate at 100%, followed by those with enterocutaneous fistulas at 84.6%, and perianal fistulizing Crohn's disease at 80%.

Canadian Relevance

No direct Canadian connection identified. Crohn's disease complications are not a Health Canada-recognized indication for hyperbaric oxygen therapy.

Study Limitations

This was an observational study, and the abstract notes there is no consensus on the optimal number or duration of HBOT sessions for these conditions.

Was this summary helpful?

Study Details

Study Type Study
Category Uncategorised
Source Pubmed
PubMed ID 33995526
Year Published 2021
Journal Gastroenterol Res Pract

Cite This Study

Share

Find a Canadian Clinic Treating Uncategorised

Browse verified hyperbaric facilities across Canada.

View Canadian Facilities

Disclaimer: This study summary is provided for informational and educational purposes only. It does not constitute medical advice. The information presented reflects the findings of the original research authors and may not represent the views of Canada Hyperbarics. Always consult a qualified healthcare professional before making treatment decisions.